$438.940
+14.441 (+3.29%)收盤時
AMGN 資訊
AMGN 事件
AstraZeneca and Amgen's Tezspire Trial Results Show Significant Improvements
Full results from the "positive" Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen's (AMGN) Tezspire demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis, despite continued treatment with background medications. These improvements were observed at week 24 in both doses tested compared to placebo. Efficacy was sustained in both doses through week 52, as measured in key secondary endpoints. Results from the CROSSING trial were presented in a late-breaking oral presentation at United European Gastroenterology Week 2026 in Barcelona, Spain. Treatment with Tezspire, administered subcutaneously every four weeks, achieved histologic remission for 64.8% for the 210mg dose and 68.9% for the 420mg dose of patients at week 24, compared to 3.5% of patients on placebo. Tezspire also reduced the frequency and severity of dysphagia symptoms by 18.8 points for the 210mg dose and 22.0 points for the 420mg dose from baseline vs. 14.7 points on placebo, as measured by the Dysphagia Symptom Questionnaire score, a patient-reported outcome measure. These results were sustained through week 52, assessed in key secondary endpoints: 67.8% (210mg dose) and 63.3% (420mg dose) of patients taking Tezspire achieved histologic remission vs. 5.4% on placebo and there was continued symptom improvement through week 52, with patients taking Tezspire achieving an average reduction from baseline of 22.1 points (210mg dose) and 24.0 points (420mg dose) in the DSQ score vs. 13.2 points on placebo.
AstraZeneca and Amgen's TEZSPIRE Shows Significant Improvement in EoE Symptoms
Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen's (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission and the frequency and severity of dysphagia in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis, EoE, despite continued treatment with background medications. These improvements were observed at week 24 in both doses tested compared to placebo. Efficacy was sustained in both doses through week 52, as measured in key secondary endpoints.
Mattel Appoints Peter Griffith as CFO
Mattel (MAT) announced the appointment of Peter Griffith as Chief Financial Officer, effective October 20, 2026. Griffith succeeds Paul Ruh, who will serve in an advisory role through the end of the year to support an effective transition. Griffith will report to Roger Lynch, Chairman and Chief Executive Officer of Mattel, and will also join the company's board of directors. Most recently, Griffith served as Executive Vice President and CFO of Amgen (AMGN)
Applied Intuition Valued at $30B, Plans to Raise Over $1B
The week's largest private market raises came from TypeSafe AI and Oratomic as investors poured money into next generation AI safety systems and fault tolerant quantum hardware.This week's private company news:Autonomous vehicle software startup Applied Intuition has received new investment offers valuing the company at $30B or more, doubling its previous valuation of $15B from June 2025, The Information's Stephanie Palazzolo. The offers are likely to encourage the company to raise at least $1B in the next few months, sources said.Some of the biggest capital raises by private companies this week include:TypeSafe AI– The company announced its Series A funding round led by Andreessen Horowitz, with Sequoia Capital, existing investor DCVC, and several angel investors also participating. The financing values TypeSafe at $7.5B, and Andreessen Horowitz general partner Martin Casado will join its board. Publicly-traded companies operating in the same space include Microsoft, Alphabet, and IBM.Oratomic– The company whose mission is to build the first fault-tolerant quantum computers announced that it has raised a $475M Series B round. Publicly-traded companies operating in the same space include IonQ, Rigetti Computing, and D-Wave Quantum.SignSplit PBC– The fast-growing technology company emerged from stealth with a $400M strategic seed round. The financing commitment, which values SignSplit at $1B, combines capital with a multi-year package of strategic resources to support SignSplit's global rollout. Publicly-traded companies operating in the same space include Cisco, Akamai, and Cloudflare.Vinci– The company announced a $250M Series B co-led by Advent, Temasek and Xora, with participation from AMD Ventures, Eclipse, Khosla Ventures, Madrona and others, valuing the company at $1.5B. Vinci is building an AI-native computational platform designed to fundamentally expand what hardware engineers can create. Publicly-traded companies operating in the same space include Synopsys, Cadence, and Ansys.Atomic Machines– The company announced that it has raised $250M. Publicly-traded companies operating in the same space include Applied Materials, Lam Research, and ASML.Unicorns to watch this week:ReliaQuest– The company remains one of the most prominent private players in AI driven security operations, with its valuation hovering around $3.4B as demand for unified threat detection platforms accelerates. Publicly-traded companies operating in the same space include Okta, Zscaler, and Crowdstrike.MaintainX– The company continues its climb in manufacturing‑tech after recently surpassing the $2.5B valuation mark, riding strong enterprise adoption of its digital maintenance and workflow platform. Publicly-traded companies operating in the same space include Fortive, ServiceNow, and ABM Industries.Enveda Biosciences– The company solidified its unicorn status with a $150M Series D, advancing its machine‑learning platform for discovering therapeutics from natural compounds. Enveda remains one of the most closely watched AI‑native drug‑discovery startups. Publicly-traded companies operating in the same space include Amgen, Bristol-Myers, and Gilead.Underdog Fantasy– Valued around $1.3B, the company continues to scale its sports gaming and pick'em platform amid rising engagement and regulatory expansion across U.S. markets. Publicly-traded companies operating in the same space include DraftKings, Flutter Entertainment, and MGM Resorts.TRM Labs– The blockchain intelligence and analytics platform used by crypto firms and regulators to investigate fraud and financial crime sits near the $1B valuation mark. Publicly-traded companies operating in the same space include Coinbase, Block, and Marathon Digital.IPOs to watch:FireFly Robotics– The company, which designs and manufactures autonomous, all-electric robotic systems for turf and grounds environments, announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public direct listing of its common stock. The company is not selling any shares and will not receive any proceeds in the direct listing.Anthropic– The company is now planning to hold its IPO in November, which is later than the October listing expected by investors, The Wall Street Journal's Corrie Driebusch, Anissa Gardizy, and Kate Clark, citing people familiar with the matter. The report states that a delayed listing would allow the company to share its Q3 results and show its strong competitive position. Anthropic also intends to meet with investors in the coming days, and the meetings are expected to help the company and its bankers gauge investor appetite for the offering, WSJ noted.Nscale Limited– The company has filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Altera Corporation– Altera announced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automation– The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions."Private Markets" is The Fly's recurring series of stories on the latest moves in the private sector, largest unicorn companies and initial public offerings to watch. Fly subscribers, add $PRIVATE to your portfolio for alerts on breaking news in the startup and venture capital space.
Gilead and Others Notable Gainers in Liquid Options This Morning
Notable gainers among liquid option names this morning include Gilead (GILD) $148.10 +3.88, NetApp (NTAP) $234.28 +5.83, Amgen (AMGN) $412.67 +10.07, Marathon Petroleum (MPC) $443.15 +10.79, and Kroger (KR) $59.70 +1.29.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。